Swedish Orphan Biovitrum AB - Company Profile
Powered by 
All the data and insights you need on Swedish Orphan Biovitrum AB in one report.
$295
- Save hours of research time and resources with
our up-to-date Swedish Orphan Biovitrum AB Strategy Report
- Understand Swedish Orphan Biovitrum AB position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Swedish Orphan Biovitrum AB Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Swedish Orphan Biovitrum AB Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 29 Nov 2022 | Lorem |
| LoA Update: University trial of SOBI’s intracerebral haemorrhage asset Kineret sees its trial advancement rate grow after Phase II trial completion | 11 Oct 2021 | Adam Zamecnik |
| Swedish Orphan’s Kineret offers potential safety advantage in COVID-19 versus Novartis’ Ilaris and anti-IL-6 antibodies, experts say | 24 Jun 2020 | Manasi Vaidya |
| Sanofi/Regeneron’s, Roche’s and Eusa’s success with IL-6-targeting antibodies for COVID-19 depends on recruiting less critically ill patients; biomarker importance emphasized by experts | 03 Apr 2020 | Manasi Vaidya;;Ayisha Sharma;;Reynald Castaneda |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer